Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib ; volume:10 ; number:1 ; day:30 ; month:7 ; year:2024 ; pages:1-7 ; date:12.2024
Surgical case reports ; 10, Heft 1 (30.7.2024), 1-7, 12.2024
- Creator
-
Funo, Takumi
Hashimoto, Daisuke
Yamaki, So
Matsumura, Kazuki
Miyazaki, Hidetaka
Matsui, Yuki
Tsybulskyi, Denys
Sang, Nguyen Thanh
Yaolin, Xu
Satoi, Sohei
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40792-024-01975-x
- URN
-
urn:nbn:de:101:1-2410230841466.787898800758
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Funo, Takumi
- Hashimoto, Daisuke
- Yamaki, So
- Matsumura, Kazuki
- Miyazaki, Hidetaka
- Matsui, Yuki
- Tsybulskyi, Denys
- Sang, Nguyen Thanh
- Yaolin, Xu
- Satoi, Sohei
- SpringerLink (Online service)
Other Objects (12)
The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance
Successful Combination of Olaparib and 225 Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy
FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer
The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance
Successful Combination of Olaparib and 225 Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy
FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer
The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance
Successful Combination of Olaparib and 225 Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy
FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy